Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Electrodiagnosis | 4 | 2020 | 14 | 2.120 |
Why?
|
| Neural Conduction | 7 | 2021 | 45 | 1.760 |
Why?
|
| Neurology | 3 | 2023 | 46 | 1.380 |
Why?
|
| Electromyography | 3 | 2020 | 150 | 1.290 |
Why?
|
| Ultrasonography | 2 | 2020 | 486 | 1.260 |
Why?
|
| Societies, Medical | 6 | 2023 | 195 | 1.210 |
Why?
|
| Neurophysiology | 5 | 2024 | 7 | 1.000 |
Why?
|
| Polyneuropathies | 3 | 2017 | 8 | 0.960 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2019 | 63 | 0.840 |
Why?
|
| Axons | 1 | 2021 | 43 | 0.810 |
Why?
|
| Dictionaries as Topic | 1 | 2020 | 1 | 0.750 |
Why?
|
| Neuromuscular Diseases | 1 | 2020 | 33 | 0.730 |
Why?
|
| Terminology as Topic | 1 | 2020 | 72 | 0.710 |
Why?
|
| Amyloid Neuropathies, Familial | 4 | 2020 | 5 | 0.590 |
Why?
|
| Oligonucleotides | 3 | 2020 | 76 | 0.510 |
Why?
|
| Disease Progression | 3 | 2020 | 915 | 0.480 |
Why?
|
| Health Care Costs | 1 | 2014 | 175 | 0.440 |
Why?
|
| Nervous System Diseases | 1 | 2014 | 97 | 0.440 |
Why?
|
| Diabetes Mellitus | 2 | 2024 | 309 | 0.420 |
Why?
|
| Amyloidosis, Familial | 1 | 2011 | 3 | 0.410 |
Why?
|
| Neurologic Examination | 1 | 2011 | 76 | 0.390 |
Why?
|
| Peripheral Nerves | 2 | 2007 | 51 | 0.380 |
Why?
|
| Oligonucleotides, Antisense | 2 | 2020 | 29 | 0.380 |
Why?
|
| Amyloid Neuropathies | 2 | 2007 | 2 | 0.380 |
Why?
|
| Diabetic Neuropathies | 2 | 2007 | 55 | 0.370 |
Why?
|
| Humans | 32 | 2024 | 54391 | 0.330 |
Why?
|
| Motor Neurons | 1 | 2007 | 31 | 0.320 |
Why?
|
| Neurons, Afferent | 1 | 2007 | 35 | 0.310 |
Why?
|
| Molecular Biology | 1 | 2007 | 31 | 0.310 |
Why?
|
| Larynx | 2 | 2020 | 39 | 0.300 |
Why?
|
| Electrocardiography | 3 | 2016 | 290 | 0.280 |
Why?
|
| Muscle, Skeletal | 3 | 2020 | 847 | 0.250 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2024 | 17 | 0.240 |
Why?
|
| Accessory Nerve Diseases | 1 | 2003 | 1 | 0.240 |
Why?
|
| Tongue Neoplasms | 1 | 2003 | 14 | 0.240 |
Why?
|
| Testicular Neoplasms | 1 | 2024 | 47 | 0.230 |
Why?
|
| Neuralgia | 1 | 2024 | 58 | 0.230 |
Why?
|
| United States | 7 | 2024 | 5208 | 0.220 |
Why?
|
| Demyelinating Diseases | 1 | 2002 | 7 | 0.210 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2002 | 12 | 0.210 |
Why?
|
| Carcinoma | 1 | 2003 | 154 | 0.210 |
Why?
|
| Blood Component Removal | 1 | 2002 | 18 | 0.210 |
Why?
|
| Virus Diseases | 1 | 2022 | 44 | 0.210 |
Why?
|
| Neuromuscular Junction | 1 | 2021 | 10 | 0.210 |
Why?
|
| Myelin Sheath | 1 | 2021 | 28 | 0.200 |
Why?
|
| Hypoglycemic Agents | 1 | 2003 | 177 | 0.200 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 489 | 0.200 |
Why?
|
| Hypersensitivity | 1 | 2022 | 83 | 0.200 |
Why?
|
| Laryngoplasty | 1 | 2020 | 7 | 0.190 |
Why?
|
| Laryngectomy | 1 | 2020 | 28 | 0.190 |
Why?
|
| Tissue Scaffolds | 1 | 2020 | 27 | 0.190 |
Why?
|
| Prealbumin | 3 | 2007 | 24 | 0.190 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2003 | 202 | 0.190 |
Why?
|
| Insulin | 1 | 2003 | 511 | 0.190 |
Why?
|
| Muscle Weakness | 1 | 2020 | 46 | 0.190 |
Why?
|
| Tissue Engineering | 1 | 2020 | 61 | 0.190 |
Why?
|
| Tibial Nerve | 2 | 2011 | 5 | 0.180 |
Why?
|
| Health Personnel | 1 | 2023 | 247 | 0.180 |
Why?
|
| Lower Extremity | 1 | 2020 | 103 | 0.180 |
Why?
|
| Action Potentials | 2 | 2011 | 131 | 0.170 |
Why?
|
| Upper Extremity | 1 | 2019 | 50 | 0.170 |
Why?
|
| Asthma | 1 | 2022 | 293 | 0.160 |
Why?
|
| Quality of Life | 2 | 2024 | 924 | 0.160 |
Why?
|
| Parainfluenza Virus 3, Human | 1 | 2017 | 7 | 0.150 |
Why?
|
| Middle Aged | 10 | 2024 | 13082 | 0.150 |
Why?
|
| Respirovirus Infections | 1 | 2017 | 8 | 0.150 |
Why?
|
| Diagnostic Techniques, Neurological | 1 | 2017 | 5 | 0.150 |
Why?
|
| Physicians | 2 | 2023 | 245 | 0.150 |
Why?
|
| Male | 13 | 2024 | 27347 | 0.150 |
Why?
|
| Sympathetic Nervous System | 1 | 2016 | 21 | 0.150 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 130 | 0.140 |
Why?
|
| Tachycardia, Ventricular | 1 | 2016 | 43 | 0.140 |
Why?
|
| Orphan Drug Production | 1 | 2015 | 1 | 0.140 |
Why?
|
| Neuromuscular Junction Diseases | 1 | 2015 | 1 | 0.140 |
Why?
|
| 4-Aminopyridine | 1 | 2015 | 3 | 0.140 |
Why?
|
| Potassium Channel Blockers | 1 | 2015 | 18 | 0.140 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 206 | 0.130 |
Why?
|
| Antineoplastic Agents | 1 | 2024 | 1300 | 0.130 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 1082 | 0.110 |
Why?
|
| Skin | 1 | 2016 | 469 | 0.110 |
Why?
|
| Vocal Cord Paralysis | 1 | 2012 | 27 | 0.110 |
Why?
|
| Evoked Potentials, Motor | 1 | 2011 | 8 | 0.100 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2011 | 40 | 0.100 |
Why?
|
| Heart Conduction System | 1 | 2011 | 25 | 0.100 |
Why?
|
| Female | 10 | 2020 | 28471 | 0.100 |
Why?
|
| Adult | 6 | 2024 | 14207 | 0.100 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2011 | 65 | 0.100 |
Why?
|
| Sural Nerve | 2 | 2007 | 7 | 0.090 |
Why?
|
| Synkinesis | 1 | 2009 | 2 | 0.090 |
Why?
|
| Phenol | 1 | 2009 | 10 | 0.090 |
Why?
|
| Sclerosing Solutions | 1 | 2009 | 14 | 0.090 |
Why?
|
| Recurrent Laryngeal Nerve Injuries | 1 | 2009 | 11 | 0.090 |
Why?
|
| Tubulin Modulators | 1 | 2009 | 40 | 0.090 |
Why?
|
| Vincristine | 1 | 2009 | 98 | 0.090 |
Why?
|
| West Nile Fever | 1 | 2008 | 5 | 0.080 |
Why?
|
| Paralysis | 1 | 2008 | 9 | 0.080 |
Why?
|
| Heart Ventricles | 1 | 2011 | 271 | 0.080 |
Why?
|
| Predictive Value of Tests | 2 | 2012 | 1045 | 0.080 |
Why?
|
| Aged | 4 | 2020 | 10060 | 0.080 |
Why?
|
| Spinal Cord Diseases | 1 | 2008 | 37 | 0.080 |
Why?
|
| Myotonic Dystrophy | 1 | 2008 | 13 | 0.080 |
Why?
|
| Echocardiography | 1 | 2011 | 392 | 0.080 |
Why?
|
| Peroneal Nerve | 1 | 2007 | 4 | 0.080 |
Why?
|
| Vibration | 1 | 2007 | 14 | 0.080 |
Why?
|
| Follow-Up Studies | 2 | 2011 | 2390 | 0.080 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2008 | 60 | 0.080 |
Why?
|
| Sensory Receptor Cells | 1 | 2007 | 14 | 0.080 |
Why?
|
| Gelsolin | 1 | 2007 | 2 | 0.080 |
Why?
|
| Apolipoprotein A-I | 1 | 2007 | 8 | 0.080 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2008 | 99 | 0.080 |
Why?
|
| Reaction Time | 1 | 2007 | 227 | 0.070 |
Why?
|
| Heart Rate | 2 | 2020 | 358 | 0.070 |
Why?
|
| Amyloid | 2 | 2003 | 29 | 0.070 |
Why?
|
| Decompression, Surgical | 1 | 2006 | 52 | 0.070 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 922 | 0.070 |
Why?
|
| Societies | 1 | 2024 | 5 | 0.060 |
Why?
|
| Genetic Variation | 2 | 2003 | 253 | 0.060 |
Why?
|
| Sciatic Nerve | 1 | 2003 | 32 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 491 | 0.060 |
Why?
|
| Survivors | 1 | 2024 | 137 | 0.060 |
Why?
|
| Certification | 1 | 2023 | 47 | 0.060 |
Why?
|
| Education, Medical, Continuing | 1 | 2023 | 79 | 0.050 |
Why?
|
| Cross-Sectional Studies | 1 | 2007 | 1696 | 0.050 |
Why?
|
| Multiple Myeloma | 1 | 2017 | 3049 | 0.050 |
Why?
|
| Respiratory Sounds | 1 | 2022 | 54 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2020 | 5612 | 0.050 |
Why?
|
| Laryngeal Cartilages | 1 | 2020 | 1 | 0.050 |
Why?
|
| Motor Endplate | 1 | 2020 | 4 | 0.050 |
Why?
|
| Swine, Miniature | 1 | 2020 | 17 | 0.050 |
Why?
|
| Phonation | 1 | 2020 | 11 | 0.050 |
Why?
|
| Recurrent Laryngeal Nerve | 1 | 2020 | 20 | 0.050 |
Why?
|
| Myoblasts | 1 | 2020 | 21 | 0.050 |
Why?
|
| Primary Cell Culture | 1 | 2020 | 65 | 0.050 |
Why?
|
| Reflex | 1 | 2020 | 33 | 0.050 |
Why?
|
| Mutation | 1 | 2007 | 1504 | 0.050 |
Why?
|
| Deglutition | 1 | 2020 | 37 | 0.050 |
Why?
|
| Symptom Assessment | 1 | 2020 | 38 | 0.050 |
Why?
|
| Child | 3 | 2022 | 7368 | 0.050 |
Why?
|
| Pain | 1 | 2003 | 405 | 0.050 |
Why?
|
| Swine | 1 | 2020 | 430 | 0.040 |
Why?
|
| Adipose Tissue | 1 | 2020 | 208 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2020 | 743 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2020 | 807 | 0.040 |
Why?
|
| Emergency Service, Hospital | 1 | 2022 | 543 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2020 | 720 | 0.040 |
Why?
|
| International Cooperation | 1 | 2017 | 62 | 0.040 |
Why?
|
| Stellate Ganglion | 1 | 2016 | 2 | 0.040 |
Why?
|
| Electrodes | 1 | 2016 | 39 | 0.040 |
Why?
|
| Disability Evaluation | 1 | 2017 | 103 | 0.040 |
Why?
|
| Genome, Viral | 1 | 2017 | 100 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2020 | 1737 | 0.040 |
Why?
|
| Respiratory Tract Infections | 1 | 2017 | 86 | 0.040 |
Why?
|
| Cross Infection | 1 | 2017 | 109 | 0.030 |
Why?
|
| Reference Values | 1 | 2016 | 354 | 0.030 |
Why?
|
| Obesity | 1 | 2024 | 1203 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 1647 | 0.030 |
Why?
|
| Stroboscopy | 1 | 2012 | 5 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2016 | 1229 | 0.030 |
Why?
|
| Observer Variation | 1 | 2012 | 139 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2017 | 1546 | 0.030 |
Why?
|
| Otolaryngology | 1 | 2012 | 58 | 0.030 |
Why?
|
| H-Reflex | 1 | 2011 | 27 | 0.030 |
Why?
|
| Electric Stimulation | 1 | 2011 | 94 | 0.030 |
Why?
|
| Adolescent | 1 | 2003 | 6900 | 0.020 |
Why?
|
| Animals | 2 | 2020 | 14409 | 0.020 |
Why?
|
| Laryngeal Muscles | 1 | 2009 | 2 | 0.020 |
Why?
|
| Vocal Cords | 1 | 2009 | 12 | 0.020 |
Why?
|
| Nerve Regeneration | 1 | 2009 | 24 | 0.020 |
Why?
|
| Laryngoscopy | 1 | 2009 | 62 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 3431 | 0.020 |
Why?
|
| Poliomyelitis | 1 | 2008 | 15 | 0.020 |
Why?
|
| Tachycardia | 1 | 2008 | 32 | 0.020 |
Why?
|
| Spinal Cord | 1 | 2008 | 153 | 0.020 |
Why?
|
| Cause of Death | 1 | 2008 | 164 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2006 | 276 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2017 | 6459 | 0.020 |
Why?
|
| Alanine | 1 | 2003 | 44 | 0.010 |
Why?
|
| Dimerization | 1 | 2003 | 58 | 0.010 |
Why?
|
| Serine | 1 | 2003 | 44 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2003 | 124 | 0.010 |
Why?
|
| Rats | 1 | 2009 | 3419 | 0.010 |
Why?
|
| Prognosis | 1 | 2008 | 2126 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2002 | 44 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2003 | 684 | 0.010 |
Why?
|
| Pedigree | 1 | 2002 | 146 | 0.010 |
Why?
|
| Haplotypes | 1 | 2002 | 105 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2008 | 1616 | 0.010 |
Why?
|
| Myocardium | 1 | 2003 | 443 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 719 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2002 | 767 | 0.010 |
Why?
|
| Risk Factors | 1 | 2008 | 3937 | 0.010 |
Why?
|
| DNA | 1 | 2002 | 581 | 0.010 |
Why?
|
| Time Factors | 1 | 2002 | 3210 | 0.010 |
Why?
|